Geneva, Switzerland and Boston, MA - 31 May 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical
company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's
reproductive health and pregnancy, today announced that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder, Tim ADAMS, CFO, and Mario
CORSO, Senior Director Investor Relations will attend the Jefferies Healthcare Conference. Management will be presenting on
Thursday June 8th at 08:30 a.m. and will be hosting one-on-one meetings at the Grand Hyatt Hotel in New York City.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization
of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic
in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs
focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ
Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com
###
Media Contact:
Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
202-955-6222 x2526
Company Contact:
CEO Office contact
Delphine Renaud
delphine.renaud@obseva.ch
+41 22 552 1550
Investor Contact
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/70181aa5-664e-4bd9-a30f-7dcaa32de878
